Voyager Therapeutics Inc’s recent filing unveils that its Chief Medical Officer Ferguson Toby unloaded Company’s shares for reported $34595.0 on Apr 02 ’25. In the deal valued at $3.43 per share,10,086 shares were sold. As a result of this transaction, Ferguson Toby now holds 157,914 shares worth roughly $0.5 million.
Then, Sandrock Alfred sold 10,885 shares, generating $37,336 in total proceeds. Upon selling the shares at $3.43, the President and CEO now owns 430,931 shares.
Before that, Sandrock Alfred bought 10,885 shares. Voyager Therapeutics Inc shares valued at $37,369 were divested by the Officer at a price of $3.43 per share.
Cantor Fitzgerald initiated its Voyager Therapeutics Inc [VYGR] rating to an Overweight in a research note published recently. A number of analysts have revised their coverage, including Citigroup’s analysts, who began to cover the stock in early December with a ‘”a Buy”‘ rating. Leerink Partners started covering the stock on October 16, 2024. It rated VYGR as “an Outperform”.
Price Performance Review of VYGR
On Tuesday, Voyager Therapeutics Inc [NASDAQ:VYGR] saw its stock fall -0.32% to $3.16. Over the last five days, the stock has gained 2.76%. Voyager Therapeutics Inc shares have fallen nearly -62.51% since the year began. Nevertheless, the stocks have fallen -44.27% over the past one year. While a 52-week high of $9.55 was reached on 01/07/25, a 52-week low of $2.64 was recorded on 05/30/25.
Levels Of Support And Resistance For VYGR Stock
The 24-hour chart illustrates a support level at 3.13, which if violated will result in even more drops to 3.10. On the upside, there is a resistance level at 3.22. A further resistance level may holdings at 3.28.
How much short interest is there in Voyager Therapeutics Inc?
A steep rise in short interest was recorded in Voyager Therapeutics Inc stocks on 2025-06-30, growing by 1.25 million shares to a total of 4.44 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-30 was 3.2 million shares. There was a rise of 28.04%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on March 26, 2024 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $22 price target.
